InnoMed PredTox Consortium Members Present Preliminary Study Results

Basel, Switzerland, May 15, 2008

The 20 leading pharmaceutical companies, academic research organizations and technology providers participating in the European InnoMed PredTox project aim to make more informed decisions earlier in preclinical safety evaluation by combining results from molecular profiling (omics) technologies together with the findings from conventional toxicology. For this purpose, the InnoMed PredTox consortium members have been compiling a comprehensive set of preclinical toxicology data, studying two reference compounds and 14 proprietary compounds that had previously failed in clinical development for toxicity reasons.

At the 47th annual meeting of the Society of Toxicology earlier this year, InnoMed PredTox presented joint analyses of the compiled transcriptomics, proteomics and metabolomics profiling data with conventional toxicological endpoints in blood, urine, liver and kidney samples from rats. The results nicely demonstrate the merits of the systematic, integrated approach adopted by the consortium, and pave the way towards new biomarkers, a better mechanistic understanding of individual toxicological responses, and subsequently to more efficient development processes.

Genedata has provided the computational infrastructure for InnoMed PredTox, in particular the software for data management and analysis. Developed as a customization of the Genedata Expressionist® database, the PredTox database currently hosts about 1.3 TB of data and represents the central access point for the consortium members. Data analysis services based on the Genedata Expressionist product suite facilitate the comparison of data between sites and accross compounds, which proves to be essential for biological interpretation by the InnoMed PredTox toxicology experts.

“I am very happy about the success of the InnoMed PredTox project, as it validates Genedata`s philosophy of supporting the integrated analysis of large sets of different omics technologies and clinical data. With our Genedata Expressionist platform, we provide a scalable system for efficient biomarker discovery,” said Dr. Othmar Pfannes, CEO of Genedata.

About InnoMed PredTox
InnoMed PredTox aims at reducing a key bottleneck in the R&D process, namely the assessment of drug safety before new drugs enter the market. It has secured €8 million of budget over 40 months, partly funded by the European Commission Life Sciences, Genomics and Biotechnology for Health Priority (LSHB-CT-2005-518170). The project is coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a body representing the research-based pharmaceutical industry and biotech SMEs operating in Europe. The members in the consortium include: Bayer Schering Pharma AG, Boehringer Ingelheim, F. Hoffmann-La Roche , Johnson & Johnson Pharmaceutical R & D, Lilly S.A., Merck KGaA, MerckSerono, Nycomed, Novo Nordisk A/S, DK, Novartis, Organon, Sanofi-Aventis (Germany, France), Servier, the Universities of Dublin, Hacettepe and Würzburg, as well as Bio-Rad and Genedata. For more information please visit

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US.

Allison Kurz
Marketing & Communications
Phone: +41 61 511 8459

Jackie Thrasivoulos
Public Relations
Phone: +1 508 881 3109


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.